Results from an interim analysis of the randomized, open-label phase III KEYNOTE-177 study indicated that front-line therapy with the immune checkpoint inhibitor pembrolizumab (Keytruda) doubled progression-free survival (PFS) compared to chemotherapy in patients with advanced colorectal cancer.
The findings, presented at the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program, are the first to show benefit with pembrolizumab in this patient population when used as a front-line therapy.
Thierry André, MD, of the Sorbonne Université and Hôpital Saint Antoine in Paris, spoke with CancerNetwork® about the implications of the study and how these long awaited trial results could alter the current standard of care.
For me, it’s a good way to deal with the patients. Because it’s not to give a product for a large population and to obtain the…